S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
NASDAQ:VSTM

Verastem (VSTM) Stock Forecast, Price & News

$11.16
-0.04 (-0.36%)
(As of 05:22 PM ET)
Compare
Today's Range
$10.90
$11.26
50-Day Range
$4.20
$144.72
52-Week Range
$3.47
$17.52
Volume
107,554 shs
Average Volume
158,185 shs
Market Capitalization
$186.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.20

Verastem MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
287.1% Upside
$43.20 Price Target
Short Interest
Healthy
5.87% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.02mentions of Verastem in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$8,625 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.04) to ($3.72) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

226th out of 981 stocks

Pharmaceutical Preparations Industry

103rd out of 475 stocks


VSTM stock logo

About Verastem (NASDAQ:VSTM) Stock

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Receive VSTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter.

VSTM Stock News Headlines

Verastem (NASDAQ:VSTM) Shares Gap Down to $12.24
[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
Mizuho Securities Keeps Their Hold Rating on Verastem (VSTM)
Verastem Oncology Announces Reverse Stock Split
0LOV.L - Verastem, Inc.
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
StockNews.com Begins Coverage on Verastem (NASDAQ:VSTM)
StockNews.com Initiates Coverage on Verastem (NASDAQ:VSTM)
Verastem (VSTM) Receives a Buy from RBC Capital
Verastem: Q1 Earnings Snapshot
Verastem: Q1 Earnings Insights
See More Headlines

VSTM Price History

VSTM Company Calendar

Last Earnings
3/14/2023
Today
6/08/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:VSTM
CUSIP
92337C10
Fax
N/A
Employees
48
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$43.20
High Stock Price Forecast
$72.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+292.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-73,810,000.00
Pretax Margin
-2,843.30%

Debt

Sales & Book Value

Annual Sales
$2.60 million
Book Value
$2.71 per share

Miscellaneous

Free Float
16,247,000
Market Cap
$184.03 million
Optionable
Optionable
Beta
0.71

Key Executives

  • Brian M. StuglikBrian M. Stuglik
    Chief Executive Officer & Director
  • Dan PatersonDan Paterson
    President & Chief Operating Officer
  • Daniel Calkins
    VP, Chief Financial & Accounting Officer
  • Jonathan Pachter
    Chief Scientific Officer
  • Louis J. Denis
    Chief Medical Officer













VSTM Stock - Frequently Asked Questions

Should I buy or sell Verastem stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VSTM shares.
View VSTM analyst ratings
or view top-rated stocks.

What is Verastem's stock price forecast for 2023?

6 brokers have issued 1 year price objectives for Verastem's shares. Their VSTM share price forecasts range from $24.00 to $72.00. On average, they expect the company's share price to reach $43.20 in the next twelve months. This suggests a possible upside of 292.7% from the stock's current price.
View analysts price targets for VSTM
or view top-rated stocks among Wall Street analysts.

How have VSTM shares performed in 2023?

Verastem's stock was trading at $4.83 at the beginning of the year. Since then, VSTM stock has increased by 127.7% and is now trading at $11.00.
View the best growth stocks for 2023 here
.

Are investors shorting Verastem?

Verastem saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 981,400 shares, a decrease of 21.5% from the April 30th total of 1,250,000 shares. Based on an average trading volume of 649,600 shares, the days-to-cover ratio is presently 1.5 days.
View Verastem's Short Interest
.

When is Verastem's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our VSTM earnings forecast
.

How were Verastem's earnings last quarter?

Verastem, Inc. (NASDAQ:VSTM) issued its quarterly earnings data on Tuesday, March, 14th. The biopharmaceutical company reported ($0.96) EPS for the quarter.

When did Verastem's stock split?

Verastem shares reverse split on the morning of Thursday, June 1st 2023. The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is Robert Forrester's approval rating as Verastem's CEO?

11 employees have rated Verastem Chief Executive Officer Robert Forrester on Glassdoor.com. Robert Forrester has an approval rating of 100% among the company's employees. This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Verastem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (gild), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Amarin (AMRN) and Viking Therapeutics (VKTX).

What is Verastem's stock symbol?

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

Who are Verastem's major shareholders?

Verastem's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baker BROS. Advisors LP (12.71%), Acadian Asset Management LLC (1.24%), Geode Capital Management LLC (0.94%), Two Sigma Advisers LP (0.30%), Dimensional Fund Advisors LP (0.23%) and Two Sigma Investments LP (0.09%). Insiders that own company stock include Brian M Stuglik, Dan Paterson, Daniel Calkins, Ra Capital Management, LP, Robert E Gagnon and Timothy J Barberich.
View institutional ownership trends
.

How do I buy shares of Verastem?

Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verastem's stock price today?

One share of VSTM stock can currently be purchased for approximately $11.00.

How much money does Verastem make?

Verastem (NASDAQ:VSTM) has a market capitalization of $184.03 million and generates $2.60 million in revenue each year. The biopharmaceutical company earns $-73,810,000.00 in net income (profit) each year or ($4.4418) on an earnings per share basis.

How can I contact Verastem?

Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The official website for the company is www.verastem.com. The biopharmaceutical company can be reached via phone at (781) 292-4200 or via email at bsullivan@verastem.com.

This page (NASDAQ:VSTM) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -